Japanese drugmaker Shionogi & Co. said its experimental Covid-19 vaccine was found safe and effective in a study, creating an indigenous supply source for the Asian nation that is racing to complete a booster drive in hopes of curbing future outbreaks.
The recombinant protein-based vaccine that was being tested as a booster shot met its primary endpoint in the Phase 2/3 trials, Osaka-based Shionogi said in a statement Friday announcing the interim report’s findings. There were no serious treatment-related adverse events, deaths or adverse events of special interest, it said.
